Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptoms.

  • 2010-09-26
  • Archives of gynecology and obstetrics 284(2)
    • Phongthorn Virojchaiwong
    • Visut Suvithayasiri
    • Arunporn Itharat

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 26
Population
52 hysterectomized women with menopausal symptoms who had an indication for hormone therapy
Methods
Randomized, double-blind study; women received either Pueraria mirifica 25 mg or 50 mg tablet for 6 months
Blinding
Double-blind
Duration
6 months

Purpose

To compare Pueraria mirifica 25 and 50 mg dosages to relieve menopausal symptoms.

Methods

A double-blind study was conducted on 52 hysterectomized women with menopausal symptoms who had an indication for hormone therapy. The women were randomly allocated into two groups receiving either Pueraria mirifica 25 mg tablet (Arm A; n = 26) or Pueraria mirifica 50 mg (Arm B; n = 26) for 6 months. Menopausal symptoms, physical examination findings, and laboratory data were recorded at baseline. Symptoms were reevaluated at 3 and 6 months, while physical and laboratory examinations were evaluated at 1 month and at the end of treatment. A modified Green climacteric scale was used to evaluate menopausal symptoms; a score of ≥ 15 indicated estrogen deficiency.

Results

All women completed the study. Mean baseline climacteric scores of women who received 25 and 50 mg were: 24.19 ± 9.11 versus 23.19 ± 7.89, respectively (p = 0.674). After 3 and 6 months of treatment, scores were 17.92 ± 10.40 versus 15.35 ± 8.44 (p = 0.332) and 14.08 ± 10.30 versus 12.46 ± 6.38 (p = 0.500), respectively. No significant side effects were observed with Pueraria mirifica 25 or 50 mg.

Conclusions

Both dosages of Pueraria mirifica were similarly effective and safe in the treatment of menopausal symptoms.

Research Insights

  • Pueraria Mirifica→Reduced Menopausal Symptoms

    After 3 and 6 months of treatment, scores were 17.92 ± 10.40 versus 15.35 ± 8.44 (p = 0.332) and 14.08 ± 10.30 versus 12.46 ± 6.38 (p = 0.500), respectively.

    Effect
    Neutral
    Effect size
    Small
    Dose
    50 mg/day

Adverse Events Reported

  • Pueraria Mirifica→Overall tolerability

    No significant side effects were observed with Pueraria mirifica 25 or 50 mg.

    Finding
    Reported
Back to top